Severe genital cutaneous toxicity with sunitinib.

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Sunitinib is an oral medication used for metastatic renal cell carcinoma.
• Serious skin reactions to sunitinib are uncommon but can necessitate treatment discontinuation.

Purpose of the Study:

• To report a case of severe genital erythema associated with sunitinib treatment.
• To highlight the importance of recognizing and managing sunitinib-induced skin toxicities.

Main Methods:

• A case report of a 70-year-old male patient with stage IV clear cell renal carcinoma treated with sunitinib.
• Observation of adverse events, including grade 3 genital erythema, following sunitinib administration.
• Discontinuation of sunitinib and initiation of supportive care, including corticosteroids.

Main Results:

• The patient developed grade 3 genital erythema after sunitinib treatment.
• The erythema resolved after sunitinib discontinuation and supportive care.
• Reintroduction of sunitinib led to a recurrence of more severe lesions.

Conclusions:

• Severe cutaneous adverse reactions to sunitinib, such as genital erythema, can occur.
• Prompt recognition and management of these toxicities are essential.
• Appropriate management may allow for the resumption of sunitinib therapy and prevent hospitalizations.